CADASIL Explained for Families | Goodyear Foundation

If someone you love just heard the word CADASIL—or if a neurologist mentioned NOTCH3—you may be sitting in a waiting room, in a car, or at the kitchen table with your heart racing.

That reaction makes sense. CADASIL is rare. The full name is long. And the internet can sound like a medical textbook written for someone else’s exam. This guide is written for families: patients, partners, adult children, and siblings who need clarity without sugarcoating—and without burying hope.

What we can offer here: plain-language education grounded in reputable sources (NIH/NINDS, NORD, GeneReviews, MedlinePlus Genetics, and major society statements).
What we cannot offer: a diagnosis, a prognosis for your person, or medical advice. Please read with your care team—and use the disclaimer at the end.

Short companion: Prefer a one-page overview? Start with our literacy page, What is CADASIL?, then come back here for the fuller family guide. Explore the whole topic map on our CADASIL hub.

What is CADASIL? (plain English)

CADASIL stands for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. In everyday language:

Cerebral — it mainly affects the brain.
Autosomal dominant — it can be passed from one parent to a child (more on inheritance below).
Arteriopathy — a disease of the arteries (blood vessels).
Subcortical infarcts — small strokes in deeper parts of the brain.
Leukoencephalopathy — changes in the brain’s white matter that show up on MRI.

CADASIL is a genetic small-vessel disease. A change (pathogenic variant, often called a mutation) in the NOTCH3 gene affects the smooth muscle cells that wrap small arteries. Over time, those vessels can thicken and become less able to deliver blood. Reduced blood flow can lead to migraines, strokes or stroke-like events, mood and thinking changes, and characteristic white-matter findings on brain MRI.

You do not need to memorize the acronym. You do deserve a clear picture of what doctors mean when they say it.

Sources: NINDS — CADASIL; MedlinePlus Genetics — CADASIL; NORD — CADASIL; GeneReviews — CADASIL.

How CADASIL shows up in families (inheritance & NOTCH3)

CADASIL is caused by pathogenic variants in NOTCH3. It is inherited in an autosomal dominant pattern. In plain terms:

One altered copy of the gene is enough to cause the condition.
Each child of a person who carries a disease-causing NOTCH3 variant has a 50% chance of inheriting that variant—and the chance is the same for sons and daughters.
Most people with CADASIL have an affected parent. De novo (new) variants—appearing for the first time in a family—are described but appear uncommon.

A hard truth families often need named out loud: family history can look “negative” even when the gene is present. Relatives may have been misdiagnosed (for example, as “regular” stroke, MS, migraine, or early dementia), may have died before modern MRI/genetic testing, or may have had milder symptoms that never led to a label.

Another honest nuance from genetics research: classic CADASIL has long been described as rare (order-of-magnitude estimates around a few cases per 100,000 people appear in patient-facing rare-disease summaries). At the same time, population genetics work summarized in GeneReviews suggests cysteine-altering NOTCH3 variants are more frequent than classic case counts alone would imply—pointing to a wider clinical spectrum, including milder small-vessel disease in some carriers. That is not a reason to panic, and not a reason to self-diagnose. It is a reason to seek genetic counseling and specialty neurology rather than relying on a single scary blog post (including this one).

Action step: If CADASIL is confirmed or strongly suspected, ask for a referral to a genetic counselor before testing asymptomatic relatives. Predictive testing is a life decision, not a checkbox.

Predictive testing of healthy adult relatives should follow genetic counseling. Testing children for this adult-onset condition is generally deferred until adulthood (or until they can consent), except in uncommon situations a genetics team identifies.

Sources: GeneReviews — CADASIL (inheritance); MedlinePlus Genetics — Inheritance; NORD — Causes / inheritance.

Common CADASIL symptoms (an honest range)

No two people with CADASIL have identical stories—even within one family. Severity, age at first symptoms, and which problems dominate can vary widely. Still, clinicians and rare-disease references repeatedly describe a recognizable cluster:

Migraine with aura

Migraine—often with aura (temporary warning symptoms such as visual zigzags, bright spots, or other sensory/neurologic changes)—is frequently an early feature. Published ranges for how often migraine occurs differ by study and summary (roughly “about one-third” in some society summaries to “up to about three-quarters” in others; aura is common among those who have migraine). Some people experience atypical or prolonged auras; rare encephalopathy-like episodes (“CADASIL coma” in older literature) are described but are not everyday events. If headaches are new, changing, or scary, that is a reason to call your clinician—not to diagnose yourself from a list.

Strokes and TIAs

Many people with CADASIL experience ischemic strokes or transient ischemic attacks (TIAs)—brief stroke-like symptoms that resolve. NORD notes that roughly three in four patients experience recurrent stroke or TIA, often beginning in mid-adulthood (commonly discussed around ages 40–50, with a wide range). Strokes may cause weakness, numbness, speech difficulty, vision change, or coordination problems. Some people have MRI evidence of small strokes without recalling a dramatic event (“silent” infarcts).

Thinking and memory changes

Cognitive changes can include trouble with attention, processing speed, planning/decision-making (“executive function”), memory, and—over time for many—more significant vascular cognitive impairment or dementia. Timelines vary. Patient-facing NIH materials note that symptoms usually progress slowly and that by later midlife/older age, cognitive impairment is common among people with CADASIL—not that every person follows the same calendar.

Mood, apathy, and mental health

Depression, anxiety, personality or behavioral changes, and apathy (loss of initiative/interest that is not “laziness”) are part of the clinical picture for many families. These are medical symptoms of a brain disease—not character flaws. Treatment and support matter.

Less common features

Seizures, movement changes, and other neurologic symptoms are reported less often. Always interpret new symptoms with a clinician who knows the full history.

Bottom line for families: Symptom lists describe possibilities across a population, not a script for your loved one. Ask your neurology team: Which of these are we watching for in this person, and what should trigger an urgent call?

Sources: NORD — Signs & Symptoms; NINDS — Symptoms; GeneReviews — Clinical characteristics; AHA Scientific Statement (2023) on inherited CNS small vessel diseases / CADASIL.

The path to diagnosis (without promising outcomes)

Families often arrive at CADASIL after years of “weird MRI,” early stroke, or multi-generational migraine-plus-stroke stories. A careful path usually looks like this—not a guarantee of any particular result:

Clinical story + family history — Unexplained white-matter changes, mid-adult stroke without typical risk factors, migraine with aura, and relatives with early stroke or vascular dementia raise suspicion—but lack of a known family history does not rule CADASIL out.
Brain MRI — MRI can show white-matter hyperintensities (sometimes with a suggestive pattern, such as involvement of anterior temporal regions in many classic cases), lacunar infarcts, microbleeds, and related small-vessel findings. Important honesty: MRI patterns can overlap with other conditions. Imaging supports suspicion; it does not, by itself, confirm CADASIL.
Genetic testing of NOTCH3 — Identifying a heterozygous pathogenic (or likely pathogenic) NOTCH3 variant is the usual way to confirm diagnosis. Testing should be ordered and interpreted in a clinical context—ideally with neurology and genetic counseling—because variant interpretation can be complex.
Skin biopsy (selected cases) — If genetic results are unclear (for example, a variant of uncertain significance), specialized skin biopsy looking for characteristic vessel changes may help. It is not the first step for everyone.
Differential diagnosis — CADASIL can be mistaken for sporadic small-vessel disease related to aging/hypertension, multiple sclerosis, or other rare genetic vessel diseases.

There is no single blood test your primary care office “just runs” that replaces specialist evaluation. If you are advocating for a loved one, it is reasonable to ask: Should we involve a neurologist experienced in genetic small-vessel disease, and do we need genetic counseling before testing relatives?

Sources: GeneReviews — Diagnosis; NORD — Diagnosis; NINDS — Diagnosing CADASIL; EAN consensus on monogenic cerebral small-vessel diseases.

Living with CADASIL: care, research, and support

Here is the sentence families deserve said plainly: There is currently no cure and no proven disease-modifying therapy that stops CADASIL. That is the clinical reality reflected in NIH patient pages, NORD, and major society statements.

Here is the sentence that must sit beside it: Supportive care is not “nothing.” And research is active—especially natural-history and biomarker studies that make future treatment trials possible.

What care teams often focus on today

Vascular risk-factor management — Not smoking and treating blood pressure are strongly recommended to reduce added stroke risk. They are important; they are not a proven way to stop CADASIL or guarantee a slower course.
Symptom-directed care — migraine prevention/treatment plans individualized by a clinician who understands CADASIL; treatment for depression/anxiety; cognitive support and safety planning as needs change. Some migraine medicines that narrow blood vessels (including certain triptans and ergot-type drugs) are often avoided or used only with extra caution in CADASIL; evidence is limited and practice varies. Do not start or stop these based on this article—ask a neurologist who knows CADASIL.
Stroke preparedness — knowing local emergency signs and having a plan. Emergency clot-busting treatment for acute stroke is a stroke-team decision based on individual criteria—not something to self-direct.
Blood thinners and antiplatelets — Daily antiplatelet pills for preventing a first stroke in CADASIL are unproven. Even after a prior stroke or TIA, antiplatelet choices are individualized—CADASIL-specific benefit is uncertain, and bleeding risk on brain MRI matters. Blood thinners (anticoagulants) are generally considered only when there is a separate reason (such as atrial fibrillation). Discuss with a neurologist who knows CADASIL; do not copy online regimens.
Genetic counseling for the wider family when a pathogenic variant is known.

Where hope lives without hype

Researchers are studying how NOTCH3-related disease progresses, which MRI and blood markers track change, and—still largely early/preclinical for true gene-targeted approaches—how future therapies might work. For families, the practical move is: ask your neurologist about reputable registries and ClinicalTrials.gov listings, and be wary of marketing that bolts “CADASIL” onto unrelated stem-cell menus.

Practical supports that help this week

Write down questions before appointments (inheritance, driving, work, mood, headache plan, emergency plan).
Identify one clinician who will coordinate neurology + primary care.
Protect caregiver bandwidth—apathy and cognitive change are medical, and families burn out quietly.
Connect with credible patient organizations and our Foundation education hub as you build your village.

Sources: NINDS — Treating CADASIL / research; NORD — Standard Therapies; AHA 2023 Scientific Statement; ClinicalTrials.gov search: CADASIL.

Soft CTA: walk with The Goodyear Foundation

The Goodyear Foundation is a Sheridan, Wyoming nonprofit building education and community wellness support for CADASIL families—and for neighbors navigating chronic illness more broadly. We are not the corporate foundation of The Goodyear Tire & Rubber Company; if you landed here looking for tire-company philanthropy, you’ve found a different organization with a different mission.

We are pursuing 501(c)(3) status and cannot accept donations yet. What we can invite you into is the build itself:

Explore our CADASIL knowledge hub
Share the short literacy page with relatives who need a gentler on-ramp: What is CADASIL?
Follow the Build and stay connected via Get involved

You do not have to become an expert overnight. You only have to take the next clear step—with better language, better questions, and a community that refuses to leave families alone with a rare diagnosis.

Sources

National Institute of Neurological Disorders and Stroke (NINDS). CADASIL. https://www.ninds.nih.gov/health-information/disorders/cadasil
National Organization for Rare Disorders (NORD). CADASIL. https://rarediseases.org/rare-diseases/cadasil/
Hack RJ, Rutten J, Lesnik Oberstein SAJ. CADASIL. GeneReviews®. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK1500/
MedlinePlus Genetics. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. https://medlineplus.gov/genetics/condition/cerebral-autosomal-dominant-arteriopathy-with-subcortical-infarcts-and-leukoencephalopathy/
Meschia JF, et al. Management of Inherited CNS Small Vessel Diseases: The CADASIL Example: A Scientific Statement From the American Heart Association. Stroke. 2023. https://www.ahajournals.org/doi/10.1161/STR.0000000000000444
Mancuso M, et al. Monogenic cerebral small‐vessel diseases: diagnosis and therapy. European Academy of Neurology consensus. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14183
ClinicalTrials.gov — search “CADASIL”. https://clinicaltrials.gov/

Medical disclaimer

This article is for education and community support only. It is not medical advice, diagnosis, or treatment. CADASIL care decisions—including genetic testing, imaging, migraine medicines, blood thinners, acute stroke care, and participation in research—must be made with qualified clinicians who know your (or your loved one’s) full history. Do not start, stop, or change any medication based on this page. If you are experiencing stroke warning signs (face drooping, arm weakness, speech difficulty, sudden severe symptoms), call emergency services immediately.

The Goodyear Foundation (Sheridan, WY) provides information to help families ask better questions. We do not replace your medical team. Content is reviewed for accuracy against reputable sources; it may be updated as science and guidance evolve. Synapse clinical clearance (approve with edits): September 2026. Published with Dalton go-live approval.

© The Goodyear Foundation — Communications (Cadence). Distinct from The Goodyear Tire & Rubber Company and any related corporate foundations.

CADASIL, Explained for Families